Perspectives of parents receiving normal results from genomic newborn screening: a mixed-methods evaluation from the early check program

As genomic technologies become increasingly practicable for public health application, research programs are exploring population-scale genomic newborn screening (gNBS). <i>Early Check</i> is a statewide newborn screening research program in North Carolina that offers optional whole genome sequencing-based screening to parents of newborns through an electronic education, consent, and return of results platform. Parents can elect to receive screening for over 200 monogenic conditions and risk for type 1 diabetes (T1D) using a genetic risk score (GRS). To address knowledge gaps in gNBS implementation, we conducted a concurrent mixed-methods study evaluating the feasibility, acceptability, and effectiveness of the program's electronic education, consent, and return of results processes among participants who received normal screening results. We emailed the evaluation survey link to consenting parents of all participating newborns with screening results showing no increased risk identified (n = 3,496). Survey respondents could indicate their willingness to participate in an interview. A total of 279 surveys and 14 interviews were included for quantitative and qualitative analysis. Findings revealed high levels of satisfaction (94.8% positive attitude). Overall, levels of regret were low, with two-thirds of respondents reporting no regret and an additional quarter reporting mild regret. Nonetheless, the proportion reporting mild regret indicates that a meaningful subset experienced some degree of uncertainty or second thoughts. Additionally, there was generally moderate comprehension overall, with 60.9% of parents demonstrating adequate knowledge when assessed across key items. Parents' frequently-endorsed motivators included learning about their baby's future health, the study being free, and the study not requiring extra blood samples. Although most appreciated the convenience and clarity of the process, some requested more information on topics including genetic testing and T1D GRS. Parents reported limited use of the educational videos and laboratory-generated screening reports, but most viewed the lay summary of normal results. Despite this selective engagement, they described the overall experience as accessible and well-designed. Parents' decisions to share results were primarily confined to family members, with fewer disclosures to healthcare providers. This study supports the feasibility and acceptability of large-scale electronic consent and return of results processes but highlights some challenges in comprehension and equity across diverse populations.

Authors

Institutions

Publication Details

Journal
Frontiers in Genetics
Published
2025-12-03
DOI
https://doi.org/10.3389/fgene.2025.1704364
Primary Topic
Genomics and Rare Diseases
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Perspectives of parents receiving normal results from genomic newborn screening: a mixed-methods evaluation from the early check program

Holly L. Peay, Heidi Cope, Sara M. Andrews, Sean N. Halpin et al.
Frontiers in Genetics
Genomics and Rare Diseases
article

Perspectives of parents receiving normal results from genomic newborn screening: a mixed-methods evaluation from the early check program

Holly L. Peay, Heidi Cope, Sara M. Andrews, Sean N. Halpin, Curt Scharfe, Katherine C. Okoniewski, Melissa Raspa, Angela Gwaltney, Samantha Scott
article en

Abstract

As genomic technologies become increasingly practicable for public health application, research programs are exploring population-scale genomic newborn screening (gNBS). <i>Early Check</i> is a statewide newborn screening research program in North Carolina that offers optional whole genome sequencing-based screening to parents of newborns through an electronic education, consent, and return of results platform. Parents can elect to receive screening for over 200 monogenic conditions and risk for type 1 diabetes (T1D) using a genetic risk score (GRS). To address knowledge gaps in gNBS implementation, we conducted a concurrent mixed-methods study evaluating the feasibility, acceptability, and effectiveness of the program's electronic education, consent, and return of results processes among participants who received normal screening results. We emailed the evaluation survey link to consenting parents of all participating newborns with screening results showing no increased risk identified (n = 3,496). Survey respondents could indicate their willingness to participate in an interview. A total of 279 surveys and 14 interviews were included for quantitative and qualitative analysis. Findings revealed high levels of satisfaction (94.8% positive attitude). Overall, levels of regret were low, with two-thirds of respondents reporting no regret and an additional quarter reporting mild regret. Nonetheless, the proportion reporting mild regret indicates that a meaningful subset experienced some degree of uncertainty or second thoughts. Additionally, there was generally moderate comprehension overall, with 60.9% of parents demonstrating adequate knowledge when assessed across key items. Parents' frequently-endorsed motivators included learning about their baby's future health, the study being free, and the study not requiring extra blood samples. Although most appreciated the convenience and clarity of the process, some requested more information on topics including genetic testing and T1D GRS. Parents reported limited use of the educational videos and laboratory-generated screening reports, but most viewed the lay summary of normal results. Despite this selective engagement, they described the overall experience as accessible and well-designed. Parents' decisions to share results were primarily confined to family members, with fewer disclosures to healthcare providers. This study supports the feasibility and acceptability of large-scale electronic consent and return of results processes but highlights some challenges in comprehension and equity across diverse populations.

Frontiers in GeneticsVol. 16
RTI International (US)
Sanofi, Leona M. and Harry B. Helmsley Charitable Trust, Juvenile Diabetes Research Foundation United States of America, Janssen Pharmaceuticals
Openalex Percentile: Top 60%
Genomics and Rare Diseases
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.